Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coltene Holding AGCLHLF 68 Debt-to-EBITDA is 1.53 as of Dec. 2025, which is 6% above its 10-year median of 1.44. GuruFocus rates CLHLF with a GF Score™ of 68/100 and a GF Value™ of $67.48. The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Coltene Holding AG ranks worse than 54.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Coltene Holding AG's Debt-to-EBITDA or its related term are showing as below:
CLHLF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.27 Med: 1.44 Max: 2.03
Current: 1.8
During the past 13 years, the highest Debt-to-EBITDA Ratio of Coltene Holding AG was 2.03. The lowest was 0.27. And the median was 1.44.
CLHLF's Debt-to-EBITDA is ranked worse than 54.39% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs CLHLF: 1.80
Coltene Holding AG (OTCPK:CLHLF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Coltene Holding AG Debt-to-EBITDA Related Terms
Coltene Holding AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Coltene Holding AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLHLF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Coltene Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coltene Holding AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coltene Holding AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Coltene Holding AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Coltene Holding AG (CLHLF) has a Debt-to-EBITDA of 1.53 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coltene Holding AG. This is near median its historical median of 1.44. Over the past decade, Coltene Holding AG's Debt-to-EBITDA has ranged from 0.27 to 2.03. According to the industry distribution chart, Coltene Holding AG ranks #254 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 54.4%.
Is Coltene Holding AG's Debt-to-EBITDA too high?
Coltene Holding AG's current Debt-to-EBITDA of 1.53 is near median its 10-year median of 1.44. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.03. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Coltene Holding AG's value of 1.53 is 4.4% below this industry median. Based on the distribution chart, Coltene Holding AG ranks #254 out of 467 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coltene Holding AG has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Coltene Holding AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coltene Holding AG ranks #254 out of 467 companies for Debt-to-EBITDA. This places Coltene Holding AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. Coltene Holding AG's value of 1.53 is 4.4% below this benchmark. Historically, Coltene Holding AG's own Debt-to-EBITDA has ranged from 0.27 to 2.03 over the past decade. While the company's 10-year median is 1.44 vs. the industry median of 1.60, Coltene Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coltene Holding AG's current Debt-to-EBITDA of 1.53 is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Coltene Holding AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coltene Holding AG's current Debt-to-EBITDA is 1.53, which is near median its own 10-year median of 1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coltene Holding AG stock overvalued right now?
Coltene Holding AG (CLHLF) has a current Debt-to-EBITDA of 1.53. The stock's GF Value™ is $67.48, compared to a current price of $61.16 — trading 9.4% below its estimated fair value. The current Debt-to-EBITDA is 1.53, which is near median its 10-year median of 1.44 and 4.4% below the Medical Devices & Instruments industry median of 1.60. Coltene Holding AG's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Coltene Holding AG (CLHLF), the current Debt-to-EBITDA is 1.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coltene Holding AG (CLHLF) Overvalued in 2026?
Based on GuruFocus' analysis, Coltene Holding AG stock appears to be undervalued.
The current stock price of $61.16 is trading 9.4% below its estimated GF Value™ of $67.48.
Key valuation signals for CLHLF:
Debt-to-EBITDA: 1.53 (near median its 10-year median of 1.44)
GF Value™: $67.48 vs. price of $61.16 (9.4% below fair value)
Industry Position: 4.4% below the Medical Devices & Instruments median (#254 of 467)
No single metric tells the full story. See the CLHLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coltene Holding AG is a manufacturer and distributor of consumables and small devices for dental practices, dental service organisations (DSOs), dental clinics and laboratories, as well as for non-dental niches (e.g., clinics for ophthalmology or podiatry). The Group develops, manufactures, and sells mainly via distribution channels a broad and comprehensive range of disposables, tools, and equipment for dentists and dental laboratories. Geographically, it operates in EMEA, North America, Latin America, and Asia/Oceania, with maximum from North America.
68GF Score
Get the complete analysis for CLHLF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLHLF has been successfully added to your 
